Gespeichert in:
| Titel: | Formulating Poorly Water Soluble Drugs |
|---|---|
| Von: |
edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller.
|
| Person: |
Williams III, Robert O.
Davis Jr., Daniel A. Miller, Dave A. editor. |
| Körperschaft: | |
| Weitere beteiligte Personen: | , , |
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
Cham :
Springer International Publishing : Imprint: Springer,
2022.
|
| Ausgabe: | 3rd ed. 2022. |
| Schriftenreihe: | AAPS Advances in the Pharmaceutical Sciences Series,
50 |
| Schlagwörter: | |
| Medienzugang: | https://doi.org/10.1007/978-3-030-88719-3 |
| Zusammenfassung: | The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble. |
| Umfang: | 1 Online-Ressource (XII, 693 p. 280 illus., 138 illus. in color.) |
| ISBN: | 9783030887193 |
| ISSN: | 2210-738X ; |
Internformat
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | ZDB-2-SBL-978-3-030-88719-3 | ||
| 003 | DE-He213 | ||
| 005 | 20240321220153.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 220519s2022 sz | o |||| 0|eng d | ||
| 020 | |a 9783030887193 |9 978-3-030-88719-3 | ||
| 024 | 7 | |a 10.1007/978-3-030-88719-3 |2 doi | |
| 050 | 4 | |a RS400-431 | |
| 072 | 7 | |a PSB |2 bicssc | |
| 072 | 7 | |a SCI013040 |2 bisacsh | |
| 072 | 7 | |a PNB |2 thema | |
| 082 | 7 | |a 615.19 |2 23 | |
| 245 | 1 | 0 | |a Formulating Poorly Water Soluble Drugs |h [electronic resource] / |c edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller. |
| 250 | |a 3rd ed. 2022. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Springer, |c 2022. | |
| 300 | |a 1 Online-Ressource (XII, 693 p. 280 illus., 138 illus. in color.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a AAPS Advances in the Pharmaceutical Sciences Series, |x 2210-738X ; |v 50 | |
| 505 | 0 | |a Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs. | |
| 520 | |a The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble. | ||
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Clinical biochemistry. | |
| 650 | 1 | 4 | |a Pharmaceutics. |
| 650 | 2 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Medical Biochemistry. |
| 700 | 1 | |a Williams III, Robert O. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Davis Jr., Daniel A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Miller, Dave A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783030887186 |
| 776 | 0 | 8 | |i Printed edition: |z 9783030887209 |
| 776 | 0 | 8 | |i Printed edition: |z 9783030887216 |
| 830 | 0 | |a AAPS Advances in the Pharmaceutical Sciences Series, |x 2210-738X ; |v 50 | |
| 966 | 4 | 0 | |l DE-355 |p ZDB-2-SBL |q UBG_PDA_SBL |u https://doi.org/10.1007/978-3-030-88719-3 |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||
| 912 | |a ZDB-2-SBL | ||
| 049 | |a DE-355 | ||
Datensatz im Suchindex
| DE-BY-UBR_katkey | ZDB-2-SBL-978-3-030-88719-3 |
|---|---|
| _version_ | 1835726563078832128 |
| adam_text | |
| any_adam_object | |
| author2 | Williams III, Robert O. Davis Jr., Daniel A. Miller, Dave A. |
| author2_role | edt edt edt |
| author2_variant | i r o w iro irow j d a d jda jdad d a m da dam |
| author_corporate | SpringerLink (Online service) |
| author_corporate_role | |
| author_facet | Williams III, Robert O. Davis Jr., Daniel A. Miller, Dave A. SpringerLink (Online service) |
| building | Verbundindex |
| bvnumber | localUBR |
| callnumber-first | R - Medicine |
| callnumber-label | RS400-431 |
| callnumber-raw | RS400-431 |
| callnumber-search | RS400-431 |
| callnumber-sort | RS 3400 3431 |
| callnumber-subject | RS - Pharmacy |
| collection | ZDB-2-SBL ZDB-2-SXB |
| contents | Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs. |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 3rd ed. 2022. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04507nam a22005415i 4500</leader><controlfield tag="001">ZDB-2-SBL-978-3-030-88719-3</controlfield><controlfield tag="003">DE-He213</controlfield><controlfield tag="005">20240321220153.0</controlfield><controlfield tag="007">cr nn 008mamaa</controlfield><controlfield tag="008">220519s2022 sz | o |||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783030887193</subfield><subfield code="9">978-3-030-88719-3</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-030-88719-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RS400-431</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">PSB</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">SCI013040</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">PNB</subfield><subfield code="2">thema</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.19</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Formulating Poorly Water Soluble Drugs</subfield><subfield code="h">[electronic resource] /</subfield><subfield code="c">edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">3rd ed. 2022.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cham :</subfield><subfield code="b">Springer International Publishing :</subfield><subfield code="b">Imprint: Springer,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XII, 693 p. 280 illus., 138 illus. in color.) </subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="b">PDF</subfield><subfield code="2">rda</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">AAPS Advances in the Pharmaceutical Sciences Series,</subfield><subfield code="x">2210-738X ;</subfield><subfield code="v">50</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical chemistry.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmacology.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Clinical biochemistry.</subfield></datafield><datafield tag="650" ind1="1" ind2="4"><subfield code="a">Pharmaceutics.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Pharmacology.</subfield></datafield><datafield tag="650" ind1="2" ind2="4"><subfield code="a">Medical Biochemistry.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Williams III, Robert O.</subfield><subfield code="e">editor.</subfield><subfield code="4">edt</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Davis Jr., Daniel A.</subfield><subfield code="e">editor.</subfield><subfield code="4">edt</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miller, Dave A.</subfield><subfield code="e">editor.</subfield><subfield code="4">edt</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/edt</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">SpringerLink (Online service)</subfield></datafield><datafield tag="773" ind1="0" ind2=" "><subfield code="t">Springer Nature eBook</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783030887186</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783030887209</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Printed edition:</subfield><subfield code="z">9783030887216</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">AAPS Advances in the Pharmaceutical Sciences Series,</subfield><subfield code="x">2210-738X ;</subfield><subfield code="v">50</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">UBG_PDA_SBL</subfield><subfield code="u">https://doi.org/10.1007/978-3-030-88719-3</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SXB</subfield></datafield><datafield tag="950" ind1=" " ind2=" "><subfield code="a">Biomedical and Life Sciences (SpringerNature-11642)</subfield></datafield><datafield tag="950" ind1=" " ind2=" "><subfield code="a">Biomedical and Life Sciences (R0) (SpringerNature-43708)</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield></record></collection> |
| id | ZDB-2-SBL-978-3-030-88719-3 |
| illustrated | Not Illustrated |
| indexdate | 2025-06-23T13:27:55Z |
| institution | BVB |
| isbn | 9783030887193 |
| issn | 2210-738X ; |
| language | English |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XII, 693 p. 280 illus., 138 illus. in color.) |
| psigel | ZDB-2-SBL UBG_PDA_SBL ZDB-2-SBL ZDB-2-SXB |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Springer International Publishing : Imprint: Springer, |
| record_format | marc |
| series | AAPS Advances in the Pharmaceutical Sciences Series, |
| series2 | AAPS Advances in the Pharmaceutical Sciences Series, |
| spelling | Formulating Poorly Water Soluble Drugs [electronic resource] / edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller. 3rd ed. 2022. Cham : Springer International Publishing : Imprint: Springer, 2022. 1 Online-Ressource (XII, 693 p. 280 illus., 138 illus. in color.) text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda AAPS Advances in the Pharmaceutical Sciences Series, 2210-738X ; 50 Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs. The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist's approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound's physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble. Pharmaceutical chemistry. Pharmacology. Clinical biochemistry. Pharmaceutics. Medical Biochemistry. Williams III, Robert O. editor. edt http://id.loc.gov/vocabulary/relators/edt Davis Jr., Daniel A. editor. edt http://id.loc.gov/vocabulary/relators/edt Miller, Dave A. editor. edt http://id.loc.gov/vocabulary/relators/edt SpringerLink (Online service) Springer Nature eBook Printed edition: 9783030887186 Printed edition: 9783030887209 Printed edition: 9783030887216 |
| spellingShingle | Formulating Poorly Water Soluble Drugs AAPS Advances in the Pharmaceutical Sciences Series, Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs. Pharmaceutical chemistry. Pharmacology. Clinical biochemistry. Pharmaceutics. Medical Biochemistry. |
| title | Formulating Poorly Water Soluble Drugs |
| title_auth | Formulating Poorly Water Soluble Drugs |
| title_exact_search | Formulating Poorly Water Soluble Drugs |
| title_full | Formulating Poorly Water Soluble Drugs [electronic resource] / edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller. |
| title_fullStr | Formulating Poorly Water Soluble Drugs [electronic resource] / edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller. |
| title_full_unstemmed | Formulating Poorly Water Soluble Drugs [electronic resource] / edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller. |
| title_short | Formulating Poorly Water Soluble Drugs |
| title_sort | formulating poorly water soluble drugs |
| topic | Pharmaceutical chemistry. Pharmacology. Clinical biochemistry. Pharmaceutics. Medical Biochemistry. |
| topic_facet | Pharmaceutical chemistry. Pharmacology. Clinical biochemistry. Pharmaceutics. Medical Biochemistry. |
| work_keys_str_mv | AT williamsiiiroberto formulatingpoorlywatersolubledrugs AT davisjrdaniela formulatingpoorlywatersolubledrugs AT millerdavea formulatingpoorlywatersolubledrugs AT springerlinkonlineservice formulatingpoorlywatersolubledrugs |